You are here: Industry Insights > Janssen

News List

Emergent to produce drug substance for J&Js Covid-19 vaccine pharmaceutical-technology
July 07, 2020
Emergent BioSolutions has entered a five-year agreement with Johnson & Johnson unit Janssen Pharmaceutical for large-scale manufacturing of drug substance for the latter’s Covid-19 vaccine candidate, Ad26.COV2-S.
Janssen’s Ebola vaccine secures European regulatory approval pharmaceutical-technology
July 03, 2020
Johnson & Johnson unit Janssen Pharmaceutical Companies has received marketing authorisation from the European Commission (EC) for its vaccine regimen designed to prevent Ebola Virus Disease.
Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen contractpharma
June 19, 2020
Deal valued at $13.9 million; manufacturing to begin this year.
Final NICE green light for Janssen's Stelara in UC pharmatimes
June 18, 2020
The National Institute for Health and Care Excellence (NICE) has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to treat ulcerative colitis.
SC formulation of DARZALEX combination delivers deep and rapid haematologic responses and improved clinical outcomes in newly diagnosed light chain amyloidosis pharmaceutical-business-review
June 18, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the first randomised Phase 3 study investigating the subcutaneous (SC) formulation of DARZALEX (daratumumab) in the treatment of patients ...
Janssen gets EC approval for subcutaneous use of daratumumab pharmaceutical-business-review
June 09, 2020
Johnson & Johnson’s Janssen Pharmaceutical has secured approval from the European Commission for the subcutaneous formulation of Darzalex (daratumumab) for the treatment of multiple myeloma in adult patients.
EMA gives positive opinion to investigational Ebola vaccine regimen europeanpharmaceuticalreview
June 09, 2020
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
Janssen’s TREMFYA delivers improvement in psoriatic arthritis joint and skin symptoms at week 52 in phase 3 trials pharmaceutical-business-review
June 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2.
New vaccine for Ebola among CHMP recommendations pharmatimes
June 02, 2020
Johnson and Johnson's experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency's human medicines committee (CHMP) at its May meeting.
Janssen Announces Phase 1 Results for Amivantamab for Advanced NSCLC americanpharmaceuticalreview
May 21, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page